Interim report, January - June 2007

Interim report, January - June 2007

Important events in the second quarter
•  ONCOlog enters into a partnership agreement with the Belgian company IBA
•  ONCOlog receives breakthrough order for SEK 9 million
•  SACS Medical is granted 510k clearance by the FDA
•  Pharmacolog i Uppsala AB is a new portfolio company
•  LinkMed invests SEK 20 million in AnaMar Medical and IMED
•  IMED strengthens management with new CEO and Chairman
•  AbSorber, Recopharma and NovaHep move into new joint premises


Important events after the period-end
•  ONCOlog out-licences cobalt technology business concept for SEK 12 million
•  Due to a delay in the commercial launch of XM-ONE at AbSorber's distributor,
AbSorber is not expected to achieve its prognosis of a positive cash flow for
2007. LinkMed's assessment that XM-ONE should be able to achieve a market share
of 25 percent in Europe and the U.S. before 2011 remains unchanged.


Financial information for January - June, 2007
•  Results from investment operations amounted to SEK 0.0 million (0.0)
•  Other income amounted to SEK 2.5 million (1.8), of which SEK 1.3 million
(0.9) is related to the second quarter
•  Results after tax amounted to SEK -4.2 million (-6.1), of which SEK -2.0
million 
(-4.2) is related to the second quarter
•  Earnings per share were SEK -0.49 (-1.23) 
•  Shareholders' equity was SEK 292.0 million, compared to SEK 296.2 million at
December 31, 2006. Shareholders' equity per share was SEK 33.47 (33.96)
•  Equity/assets ratio was 98 percent compared to 97 percent at December 31,
2006
•  Cash and bank balances totalled SEK 172.6 million compared to SEK 202.7
million at December 31, 2006


Comments on the first six months of 2007 from CEO Ingemar Lagerlöf:
“We are delighted to register great interest for ONCOlog Medical's new products
and have great expectations for the collaboration between the Belgian company
IBA and SCC of Sweden.”
“We continue to have strong confidence in XM-ONE's long-term potential, despite
a delay in the commercial launch at our distributor.”


For additional information, please contact:
Ingemar Lagerlöf, CEO, Cell +46 70-873 2733, ingemar.lagerlof@linkmed.se 
Jan Mattsson, CFO, Cell +46 70-833 8999, jan.mattsson@linkmed.se